NCT06293950View on ClinicalTrials.gov

Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism

PHASE1RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions
Autism
Interventions
BIOLOGICAL

WJMSC

\- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.

Trial Locations (1)

00962

RECRUITING

Cell Therapy Center, Amman

All Listed Sponsors
lead

University of Jordan

OTHER